AtriCure Swings to Profit in Q2, Raises Full-Year Profitability Outlook
ATRC sits 37% above its 52-week low of $25.36.
Summary
AtriCure reported Q2 2026 revenue of $153.6 million (+12.8% YoY) and net income of $9.0 million, a sharp turnaround from a loss last year. Full-year adjusted EBITDA guidance was raised to $85–$89 million.
Key Events · Earnings and Guidance · ATRC
-
Q2 Revenue Growth of 12.8%
Worldwide revenue reached $153.6 million, driven by 13.6% U.S. growth. Pain management and appendage management were key contributors.
-
Profitability Inflection
Net income of $9.0 million ($0.18 per share) compared to a net loss of $6.2 million in Q2 2025. Adjusted EBITDA rose 78% to $27.3 million.
-
Raised Full-Year Guidance
Management now expects full-year 2026 adjusted EBITDA of $85–$89 million, up from prior implied guidance, and revenue of $602–$610 million.
-
Strong Cash Generation
The company generated $21.6 million in cash during the quarter, ending with $167.8 million in cash and equivalents.
Analysis · ATRC · Industrial Applications And Services
A sharp swing to profitability defined AtriCure's second quarter, as the company turned a prior-year net loss into a $9.0 million profit on the back of 12.8% revenue growth. Adjusted EBITDA surged 78% to $27.3 million, and cash generation reached $21.6 million. Reflecting confidence in sustained margin expansion, management raised full-year adjusted EBITDA guidance to $85–$89 million. The results mark a clear inflection point for the medical device company, driven by strength in pain management and appendage management product lines.
At the time of this filing, ATRC was trading at $34.71 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $25.36 to $43.18. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.